AU6683396A - Use of fluconazole for inhibiting the growth of cancers - Google Patents

Use of fluconazole for inhibiting the growth of cancers

Info

Publication number
AU6683396A
AU6683396A AU66833/96A AU6683396A AU6683396A AU 6683396 A AU6683396 A AU 6683396A AU 66833/96 A AU66833/96 A AU 66833/96A AU 6683396 A AU6683396 A AU 6683396A AU 6683396 A AU6683396 A AU 6683396A
Authority
AU
Australia
Prior art keywords
fluconazole
cancers
inhibiting
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU66833/96A
Other versions
AU711966B2 (en
Inventor
James Berger Camden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/674,180 external-priority patent/US5908855A/en
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of AU6683396A publication Critical patent/AU6683396A/en
Application granted granted Critical
Publication of AU711966B2 publication Critical patent/AU711966B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU66833/96A 1995-08-04 1996-07-30 Use of fluconazole for inhibiting the growth of cancers Ceased AU711966B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US188995P 1995-08-04 1995-08-04
US60/001889 1995-08-04
US08/674,180 US5908855A (en) 1996-07-16 1996-07-16 Compositions for treating viral infections
US08/674180 1996-07-16
PCT/US1996/012474 WO1997005873A2 (en) 1995-08-04 1996-07-30 Use of fluconazole for inhibiting the growth of cancers

Publications (2)

Publication Number Publication Date
AU6683396A true AU6683396A (en) 1997-03-05
AU711966B2 AU711966B2 (en) 1999-10-28

Family

ID=26669622

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66833/96A Ceased AU711966B2 (en) 1995-08-04 1996-07-30 Use of fluconazole for inhibiting the growth of cancers

Country Status (18)

Country Link
EP (1) EP0841921A2 (en)
JP (1) JPH11510187A (en)
KR (1) KR19990036138A (en)
CN (1) CN1195288A (en)
AR (1) AR003175A1 (en)
AU (1) AU711966B2 (en)
BR (1) BR9609966A (en)
CA (1) CA2229024A1 (en)
CZ (1) CZ33798A3 (en)
HU (1) HUP9903420A3 (en)
IL (1) IL123095A0 (en)
MX (1) MX9800998A (en)
NO (1) NO980473L (en)
NZ (2) NZ503921A (en)
PL (1) PL324904A1 (en)
SK (1) SK14198A3 (en)
TR (2) TR199800270T1 (en)
WO (1) WO1997005873A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
FR2742405B1 (en) * 1995-12-13 1998-02-27 Cgea Comp Gen Entre Auto DRIVE UNIT COULD BE COUPLED TO A ROLLING SPEAKER AND RESULTING VEHICLE
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
PE11499A1 (en) * 1997-05-16 1999-03-01 Procter & Gamble TREATMENT OF HIV AND CANCER
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
WO2000027428A1 (en) * 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US7004915B2 (en) * 2001-08-24 2006-02-28 Kci Licensing, Inc. Negative pressure assisted tissue treatment system
EP1895012A1 (en) 2006-08-30 2008-03-05 Universitätsklinikum Freiburg Method for inducing tumor apoptosis by increasing nitric oxide levels
US20120071539A1 (en) * 2006-12-12 2012-03-22 Emory University Compounds and methods for modulating the silencing of a polynucleotide of interest
WO2019185521A1 (en) * 2018-03-26 2019-10-03 Westfälische Wilhelms-Universität Münster Ergosterol-biosynthesis inhibitor and influenza virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196855A3 (en) * 1985-03-29 1989-04-12 Pfizer Inc. Tioconazole and related compounds for prevention of sexually transmitted diseases and control of herpetic infections
BE1004029A6 (en) * 1990-11-22 1992-09-08 Mol Omer De Pharmaceutical compound and pharmaceutical set for the treatment of cancer
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5665751A (en) * 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers

Also Published As

Publication number Publication date
HUP9903420A2 (en) 2000-03-28
IL123095A0 (en) 1998-09-24
TR199800270T1 (en) 1998-05-21
JPH11510187A (en) 1999-09-07
SK14198A3 (en) 1999-03-12
NO980473L (en) 1998-04-03
BR9609966A (en) 1999-02-02
CN1195288A (en) 1998-10-07
PL324904A1 (en) 1998-06-22
MX9800998A (en) 1998-04-30
EP0841921A2 (en) 1998-05-20
AR003175A1 (en) 1998-07-08
CZ33798A3 (en) 1998-06-17
NO980473D0 (en) 1998-02-03
TR199801739T2 (en) 1998-12-21
NZ315184A (en) 2000-05-26
HUP9903420A3 (en) 2001-12-28
WO1997005873A3 (en) 1997-03-27
AU711966B2 (en) 1999-10-28
CA2229024A1 (en) 1997-02-20
KR19990036138A (en) 1999-05-25
NZ503921A (en) 2002-03-01
WO1997005873A2 (en) 1997-02-20

Similar Documents

Publication Publication Date Title
AU6683396A (en) Use of fluconazole for inhibiting the growth of cancers
AU3180795A (en) Hydrate inhibition
EP0831880A4 (en) Antibody and antibody fragments for inhibiting the growth of tumors
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
AU5343396A (en) Quinazoline derivatives
AU5343296A (en) Quinazoline derivatives
AU5343096A (en) Quinazoline derivatives
ZA98643B (en) Method for inhibiting the growth of cancers
AU5545996A (en) Process for the preparation of triazolones
AU6683496A (en) Use of griseofulvin for inhibiting the growth of cancers
GB9719643D0 (en) Hydrate inhibition
ZA964377B (en) A pharmaceutical compositions for inhibiting the growth of cancers.
AU2871195A (en) Methods for the synthesis of diketopiperazines
AU3868095A (en) Apolipoprotein-b synthesis inhibitors
AU3769097A (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
AU4296397A (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
AU6683296A (en) Use of 1h-1,2,4-triazole derivatives for inhibiting the growth of cancers
ZA964374B (en) A pharmaceutical compositions for inhibiting the growth of cancers.
AU6106996A (en) Polymers for use as hydrate inhibitors
AU4128597A (en) Phosphatidylcholine synthesis inhibitors
AU4224096A (en) Use of phenylcyclohexylcarboxamides
AU1797392A (en) Pla2 inhibitors
AU3691093A (en) Methods of inhibiting the growth of multidrug resistant tumors
AU4712696A (en) The use of heterocyclic compounds
AU6049796A (en) Lysyloxidase inhibitors

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired